A role of WT1 in cell division and genomic stability

References

• Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet 2006; 15 Spec No 2:R196-201; PMID:16987884; http://dx.doi.org/10.1093/hmg/ddl196
   PubMed Web of Science ®Google Scholar
• Discenza MT, Pelletier J. Insights into the physiological role of WT1 from studies of genetically modified mice. Physiol Genomics 2004; 16:287-300; PMID:14966251; http://dx.doi.org/10.1152/physiolgenomics.00164.2003
   PubMed Web of Science ®Google Scholar
• Kreidberg JA. WT1 and kidney progenitor cells. Organogenesis 2010; 6:61-70; PMID:20885852; http://dx.doi.org/10.4161/org.6.2.11928
   PubMed Web of Science ®Google Scholar
• Roberts SG. Transcriptional regulation by WT1 in development. Curr Opin Genet Dev 2005; 15:542-7; PMID:16099645; http://dx.doi.org/10.1016/j.gde.2005.08.004
   PubMed Web of Science ®Google Scholar
• Rudat C, Kispert A. Wt1 and epicardial fate mapping. Circ Res 2012; 111:165-9; PMID:22693350; http://dx.doi.org/10.1161/CIRCRESAHA.112.273946
   PubMed Web of Science ®Google Scholar
• Ozdemir DD, Hohenstein P. Wt1 in the kidney–a tale in mouse models. Pediatr Nephrol 2014; 29:687-93; PMID:24240471; http://dx.doi.org/10.1007/s00467-013-2673-7
   PubMed Web of Science ®Google Scholar
• Scholz H, Kirschner KM. A role for the Wilms' tumor protein WT1 in organ development. Physiology 2005; 20:54-9; PMID:15653840; http://dx.doi.org/10.1152/physiol.00048.2004
   PubMed Web of Science ®Google Scholar
• Gao Y, Toska E, Denmon D, Roberts SG, Medler KF. WT1 regulates the development of the posterior taste field. Development 2014; 141:2271-8; PMID:24803588; http://dx.doi.org/10.1242/dev.105676
   PubMed Web of Science ®Google Scholar
• Wang XN, Li ZS, Ren Y, Jiang T, Wang YQ, Chen M, Zhang J, Hao JX, Wang YB, Sha RN, et al. The Wilms tumor gene, Wt1, is critical for mouse spermatogenesis via regulation of sertoli cell polarity and is associated with non-obstructive azoospermia in humans. PLoS Genet 2013; 9:e1003645; PMID:23935527; http://dx.doi.org/10.1371/journal.pgen.1003645
   PubMed Web of Science ®Google Scholar
• Wagner N, Wagner KD, Hammes A, Kirschner KM, Vidal VP, Schedl A, Scholz H. A splice variant of the Wilms' tumour suppressor Wt1 is required for normal development of the olfactory system. Development 2005; 132:1327-36; PMID:15716344; http://dx.doi.org/10.1242/dev.01682
   PubMed Web of Science ®Google Scholar
• Morrison AA, Viney RL, Ladomery MR. The post-transcriptional roles of WT1, a multifunctional zinc-finger protein. Biochim Biophy Acta 2008; 1785:55-62; PMID:17980713
   PubMed Web of Science ®Google Scholar
• Hartkamp J, Roberts SG. The role of the Wilms' tumour-suppressor protein WT1 in apoptosis. Biochem Soc Trans 2008; 36:629-31; PMID:18631130; http://dx.doi.org/10.1042/BST0360629
   PubMed Web of Science ®Google Scholar
• Shandilya J, Toska E, Richard DJ, Medler KF, Roberts SG. WT1 interacts with MAD2 and regulates mitotic checkpoint function. Nat Commun 2014; 5:4903; PMID:25232865; http://dx.doi.org/10.1038/ncomms5903
   PubMed Web of Science ®Google Scholar
• Chau YY, Hastie ND. The role of Wt1 in regulating mesenchyme in cancer, development, and tissue homeostasis. Trends Genet 2012; 28:515-24; PMID:22658804; http://dx.doi.org/10.1016/j.tig.2012.04.004
   PubMed Web of Science ®Google Scholar
• Huff V. Wilms' tumours: about tumour suppressor genes, an oncogene and a chameleon gene. Nat Rev Cancer 2011; 11:111-21; PMID:21248786; http://dx.doi.org/10.1038/nrc3002
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez Saiz F, Minden MD. A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21:868-76; PMID:17361230
   PubMed Web of Science ®Google Scholar
• Owen C, Fitzgibbon J, Paschka P. The clinical relevance of Wilms Tumour 1 (WT1) gene mutations in acute leukaemia. Hematol Oncol 2010; 28:13-9; PMID:20013787
   PubMed Web of Science ®Google Scholar
• Sugiyama H. WT1 (Wilms' tumor gene 1): biology and cancer immunotherapy. Japan J Clin Oncol 2010; 40:377-87; PMID:20395243; http://dx.doi.org/10.1093/jjco/hyp194
   PubMed Web of Science ®Google Scholar
• Lara-Gonzalez P, Westhorpe FG, Taylor SS. The spindle assembly checkpoint. Curr Biol 2012; 22:R966-80; PMID:23174302; http://dx.doi.org/10.1016/j.cub.2012.10.006
   PubMed Web of Science ®Google Scholar
• Fava LL, Kaulich M, Nigg EA, Santamaria A. Probing the in vivo function of Mad1:C-Mad2 in the spindle assembly checkpoint. EMBO J 2011; 30:3322-36; PMID:21772247; http://dx.doi.org/10.1038/emboj.2011.239
   PubMed Web of Science ®Google Scholar
• Han JS, Holland AJ, Fachinetti D, Kulukian A, Cetin B, Cleveland DW. Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20. Mol Cell 2013; 51:92-104; PMID:23791783; http://dx.doi.org/10.1016/j.molcel.2013.05.019
   PubMed Web of Science ®Google Scholar
• Luo X, Yu H. Protein metamorphosis: the two-state behavior of Mad2. Structure 2008; 16:1616-25; PMID:19000814; http://dx.doi.org/10.1016/j.str.2008.10.002
   PubMed Web of Science ®Google Scholar
• Mapelli M, Massimiliano L, Santaguida S, Musacchio A. The Mad2 conformational dimer: structure and implications for the spindle assembly checkpoint. Cell 2007; 131:730-43; PMID:18022367; http://dx.doi.org/10.1016/j.cell.2007.08.049
   PubMed Web of Science ®Google Scholar
• Schuyler SC, Wu YF, Kuan VJ. The Mad1-Mad2 balancing act–a damaged spindle checkpoint in chromosome instability and cancer. J Cell Sci 2012; 125:4197-206; PMID:23093575; http://dx.doi.org/10.1242/jcs.107037
   PubMed Web of Science ®Google Scholar
• Skinner JJ, Wood S, Shorter J, Englander SW, Black BE. The Mad2 partial unfolding model: regulating mitosis through Mad2 conformational switching. J Cell Biol 2008; 183:761-8; PMID:19029339; http://dx.doi.org/10.1083/jcb.200808122
   PubMed Web of Science ®Google Scholar
• Varetti G, Guida C, Santaguida S, Chiroli E, Musacchio A. Homeostatic control of mitotic arrest. Mol Cell 2011; 44:710-20; PMID:22152475; http://dx.doi.org/10.1016/j.molcel.2011.11.014
   PubMed Web of Science ®Google Scholar
• Westhorpe FG, Tighe A, Lara-Gonzalez P, Taylor SS. p31comet-mediated extraction of Mad2 from the MCC promotes efficient mitotic exit. J Cell Sci 2011; 124:3905-16; PMID:22100920; http://dx.doi.org/10.1242/jcs.093286
   PubMed Web of Science ®Google Scholar
• Yang M, Li B, Tomchick DR, Machius M, Rizo J, Yu H, Luo X. p31comet blocks Mad2 activation through structural mimicry. Cell 2007; 131:744-55; PMID:18022368; http://dx.doi.org/10.1016/j.cell.2007.08.048
   PubMed Web of Science ®Google Scholar
• Yun M, Han YH, Yoon SH, Kim HY, Kim BY, Ju YJ, Kang CM, Jang SH, Chung HY, Lee SJ, et al. p31comet Induces cellular senescence through p21 accumulation and Mad2 disruption. Mol Cancer Res 2009; 7:371-82; PMID:19276188; http://dx.doi.org/10.1158/1541-7786.MCR-08-0056
   PubMed Web of Science ®Google Scholar
• Bakhoum SF, Compton DA. Chromosomal instability and cancer: a complex relationship with therapeutic potential. J Clin Invest 2012; 122:1138-43; PMID:22466654; http://dx.doi.org/10.1172/JCI59954
   PubMed Web of Science ®Google Scholar
• Burds AA, Lutum AS, Sorger PK. Generating chromosome instability through the simultaneous deletion of Mad2 and p53. Proc Natl Acad Sci U S A 2005; 102:11296-301; PMID:16055552; http://dx.doi.org/10.1073/pnas.0505053102
   PubMed Web of Science ®Google Scholar
• Holland AJ, Cleveland DW. Losing balance: the origin and impact of aneuploidy in cancer. EMBO Rep 2012; 13:501-14; PMID:22565320; http://dx.doi.org/10.1038/embor.2012.55
   PubMed Web of Science ®Google Scholar
• Rao CV, Yamada HY, Yao Y, Dai W. Enhanced genomic instabilities caused by deregulated microtubule dynamics and chromosome segregation: a perspective from genetic studies in mice. Carcinogenesis 2009; 30:1469-74; PMID:19372138; http://dx.doi.org/10.1093/carcin/bgp081
   PubMed Web of Science ®Google Scholar
• Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 2014; 15:80-9; PMID:24387333; http://dx.doi.org/10.2174/1389450114666140106101412
   PubMed Web of Science ®Google Scholar
• Britigan EM, Wan J, Zasadil LM, Ryan SD, Weaver BA. The ARF tumor suppressor prevents chromosomal instability and ensures mitotic checkpoint fidelity through regulation of Aurora B. Mol Biol Cell 2014; 25:2761-73; PMID:25057018; http://dx.doi.org/10.1091/mbc.E14-05-0966
   PubMed Web of Science ®Google Scholar
• Dick FA, Rubin SM. Molecular mechanisms underlying RB protein function. Nat Rev Mol Cell Biol 2013; 14:297-306; PMID:23594950; http://dx.doi.org/10.1038/nrm3567
   PubMed Web of Science ®Google Scholar
• Malumbres M. Oncogene-induced mitotic stress: p53 and pRb get mad too. Cancer Cell 2011; 19:691-2; PMID:21665141; http://dx.doi.org/10.1016/j.ccr.2011.05.023
   PubMed Web of Science ®Google Scholar
• van Deursen JM. Rb loss causes cancer by driving mitosis mad. Cancer Cell 2007; 11:1-3; PMID:17222786; http://dx.doi.org/10.1016/j.ccr.2006.12.006
   PubMed Web of Science ®Google Scholar
• Giacinti C, Giordano A. RB and cell cycle progression. Oncogene 2006; 25:5220-7; PMID:16936740; http://dx.doi.org/10.1038/sj.onc.1209615
   PubMed Web of Science ®Google Scholar
• Deng CX. BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution. Nucl Acids Res 2006; 34:1416-26; PMID:16522651; http://dx.doi.org/10.1093/nar/gkl010
   PubMed Web of Science ®Google Scholar
• Werner H, Sarfstein R. Transcriptional and epigenetic control of IGF1R gene expression: implications in metabolism and cancer. Growth Horm IGF Res 2014; 24:112-8; http://dx.doi.org/10.1016/j.ghir.2014.03.006
   PubMed Web of Science ®Google Scholar
• Chi YH, Ward JM, Cheng LI, Yasunaga J, Jeang KT. Spindle assembly checkpoint and p53 deficiencies cooperate for tumorigenesis in mice. Int J Cancer 2009; 124:1483-9; PMID:19065665; http://dx.doi.org/10.1002/ijc.24094
   PubMed Web of Science ®Google Scholar
• Schvartzman JM, Duijf PH, Sotillo R, Coker C, Benezra R. Mad2 is a critical mediator of the chromosome instability observed upon Rb and p53 pathway inhibition. Cancer Cell 2011; 19:701-14; PMID:21665145; http://dx.doi.org/10.1016/j.ccr.2011.04.017
   PubMed Web of Science ®Google Scholar
• Al-Hussain T, Ali A, Akhtar M. Wilms tumor: an update. Adv Anatomic Pathol 2014; 21:166-73; PMID:24713986; http://dx.doi.org/10.1097/PAP.0000000000000017
   PubMed Web of Science ®Google Scholar
• Toska E, Roberts SG. Mechanisms of transcriptional regulation by WT1 (Wilms' tumour 1). Biochem J 2014; 461:15-32; PMID:24927120
   PubMed Web of Science ®Google Scholar
• Johnson D, Hastwell PW, Walmsley RM. The involvement of WT1 in the regulation of GADD45a in response to genotoxic stress. Mutagenesis 2013; 28:393-9; PMID:23476008; http://dx.doi.org/10.1093/mutage/get015
   PubMed Web of Science ®Google Scholar
• Busch M, Schwindt H, Brandt A, Beier M, Gorldt N, Romaniuk P, Toska E, Roberts S, Royer HD, Royer-Pokora B. Classification of a frameshift/extended and a stop mutation in WT1 as gain-of-function mutations that activate cell cycle genes and promote Wilms tumour cell proliferation. Hum Mol Genet 2014; 23:3958-74; PMID:24619359; http://dx.doi.org/10.1093/hmg/ddu111
   PubMed Web of Science ®Google Scholar
• Toska E, Campbell HA, Shandilya J, Goodfellow SJ, Shore P, Medler KF, Roberts SG. Repression of transcription by WT1-BASP1 requires the myristoylation of BASP1 and the PIP2-dependent recruitment of histone deacetylase. Cell Rep 2012; 2:462-9; PMID:22939983; http://dx.doi.org/10.1016/j.celrep.2012.08.005
   PubMed Web of Science ®Google Scholar
• Toska E, Shandilya J, Goodfellow SJ, Medler KF, Roberts SG. Prohibitin is required for transcriptional repression by the WT1-BASP1 complex. Oncogene 2014; 33:5100-8; PMID:24166496; http://dx.doi.org/10.1038/onc.2013.447
   PubMed Web of Science ®Google Scholar
• Hartkamp J, Carpenter B, Roberts SG. The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell 2010; 37:159-71; PMID:20122399; http://dx.doi.org/10.1016/j.molcel.2009.12.023
   PubMed Web of Science ®Google Scholar
• Hartkamp J, Roberts SG. HtrA2, taming the oncogenic activities of WT1. Cell Cycle 2010; 9:2508-14; PMID:20543571; http://dx.doi.org/10.4161/cc.9.13.12060
   PubMed Web of Science ®Google Scholar
• Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kondo S, Kaji M. Overexpression of MAD2 predicts clinical outcome in primary lung cancer patients. Lung Cancer 2011; 74:124-31; PMID:21376419; http://dx.doi.org/10.1016/j.lungcan.2011.01.025
   PubMed Web of Science ®Google Scholar
• McGrogan BT, Gilmartin B, Carney DN, McCann A. Taxanes, microtubules and chemoresistant breast cancer. Biochim Biophys Acta 2008; 1785:96-132; PMID:18068131
   PubMed Web of Science ®Google Scholar
• Sotillo R, Schvartzman JM, Socci ND, Benezra R. Mad2-induced chromosome instability leads to lung tumour relapse after oncogene withdrawal. Nature 2010; 464:436-40; PMID:20173739; http://dx.doi.org/10.1038/nature08803
   PubMed Web of Science ®Google Scholar
• Yu L, Liu S, Guo W, Zhang B, Liang Y, Feng Q. Upregulation of Mad2 facilitates in vivo and in vitro osteosarcoma progression. Oncol Rep 2012; 28:2170-6; PMID:22992948
   PubMed Web of Science ®Google Scholar
• Wang X, Jin DY, Wong HL, Feng H, Wong YC, Tsao SW. MAD2-induced sensitization to vincristine is associated with mitotic arrest and Raf/Bcl-2 phosphorylation in nasopharyngeal carcinoma cells. Oncogene 2003; 22:109-16; PMID:12527913; http://dx.doi.org/10.1038/sj.onc.1206069
   PubMed Web of Science ®Google Scholar
• Smolen GA, Vassileva MT, Wells J, Matunis MJ, Haber DA. SUMO-1 modification of the Wilms' tumor suppressor WT1. Cancer Res 2004; 64:7846-51; PMID:15520190; http://dx.doi.org/10.1158/0008-5472.CAN-04-1502
   PubMed Web of Science ®Google Scholar
• Ye Y, Raychaudhuri B, Gurney A, Campbell CE, Williams BR. Regulation of WT1 by phosphorylation: inhibition of DNA binding, alteration of transcriptional activity and cellular translocation. EMBO J 1996; 15:5606-15; PMID:8896454
   PubMed Web of Science ®Google Scholar
• Green LM, Wagner KJ, Campbell HA, Addison K, Roberts SG. Dynamic interaction between WT1 and BASP1 in transcriptional regulation during differentiation. Nucleic Acids Res 2009; 37:431-40; PMID:19050011; http://dx.doi.org/10.1093/nar/gkn955
   PubMed Web of Science ®Google Scholar
• Funabiki H, Wynne DJ. Making an effective switch at the kinetochore by phosphorylation and dephosphorylation. Chromosoma 2013; 122:135-58; PMID:23512483; http://dx.doi.org/10.1007/s00412-013-0401-5
   PubMed Web of Science ®Google Scholar
• Yamasaki T, Takahashi A, Pan J, Yamaguchi N, Yokoyama KK. Phosphorylation of Activation Transcription Factor-2 at Serine 121 by Protein Kinase C Controls c-Jun-mediated Activation of Transcription. J Biol Chem 2009; 284:8567-81; PMID:19176525; http://dx.doi.org/10.1074/jbc.M808719200
   PubMed Web of Science ®Google Scholar
• Mochly-Rosen D, Das K, Grimes KV. Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 2012; 11:937-57; PMID:23197040; http://dx.doi.org/10.1038/nrd3871
   PubMed Web of Science ®Google Scholar
• Toton E, Ignatowicz E, Skrzeczkowska K, Rybczynska M. Protein kinase Cepsilon as a cancer marker and target for anticancer therapy. Pharmacol Rep 2011; 63:19-29; PMID:21441608; http://dx.doi.org/10.1016/S1734-1140(11)70395-4
   PubMed Web of Science ®Google Scholar